Rights to antibody drug from China’s Keymed change hands in Gilead acquisition of Ouro
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences,...









